* If you want to update the article please login/register
This paper explores long-term effects of burn patients treated with oxandrolone and bisphosphonates. Methods We looked at a deidentified database of electronic medical records for over 55 healthcare organizations, including over 75 million patients. Patients were admitted within one month of injury to either oxandrolone or bisphosphonate. During the study period, we observed 280,367 patients with burn injuries. Compared to those who did not, oxandrolone-infused oxandrolone and fractured long bones were both significantly lower among matched patients and fractured long bones. Patients receiving oxandrolone acute kidney disease were up compared to those not receiving the drug, but chronic kidney disease was reduced. There was no rise in acute or persistent kidney disease among patients receiving a bisphosphonate. Conclusions Oxandrolone and bisphosphonate medications have been well researched and have been shown to reduce bone density loss after burn injury. Patients receiving oxandrolone were reduced in fractured bones and especially long bones, implying that reduced bone catabolism during the acute recovery period may provide long-term injury prevention. While we do see an increase in mortality with both of these drugs, we do not see any increase in liver disease or persistent kidney disease, implying that causes unrelated to the administration of these drugs are contributing to the rise in mortality and could be related to selection bias. This is the first report to find that oxandrolone reduces the risk of fractures following burn injury.
Source link: https://europepmc.org/article/MED/PMC8945503
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions